Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods and compositions for inhibiting HIV transmission

A composition and animal technology, applied in the field of medicine, can solve the problem of not protecting the infection of the African green monkey homologous virus and the like

Inactive Publication Date: 2013-06-19
REEF PHARMA PTY LTD
View PDF38 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For example, vaccination with inactivated SIV did not protect African green monkeys from infection by the homologous virus despite a strong immune response to SIV

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for inhibiting HIV transmission
  • Methods and compositions for inhibiting HIV transmission
  • Methods and compositions for inhibiting HIV transmission

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0183] Example 1: Preparation of hyperimmune colostrum comprising polyclonal anti-Env antibodies

[0184] Step 1 - Vaccine Preparation for Dairy Cows

[0185] The methods for preparing antigens reported in Publication No. WO / 2004 / 078209, International Application No. PCT / AU2004 / 000277 (the contents of which are incorporated herein by reference) were used.

[0186] Step 2 - used the method reported in Publication No. WO / 2004 / 078209, International Application No. PCT / AU2004 / 000277 (the contents of which are incorporated herein by reference) for the preparation of antibodies from vaccinated cows Methods.

Embodiment 2

[0187] Example 2: Preparation of Polyclonal Antibody Binding to HIV Env and Confirmation of Neutralization

[0188] Soluble Env gp140 oligomers have been prepared from Clade A, B and C HIV strains from Hela and / or 293T cells and purified by lentil agglutinin affinity chromatography and gel filtration chromatography.

[0189] Four dairy cows (two in the second semester and two initially non-pregnant) were vaccinated with 100 μg of purified HIV-1 Env gp140 oligomer in Montanide adjuvant. Two groups of two each were inoculated with clade B only (AD8) or with equal amounts (33.33 μg) of clade A, B and C Env gp140 (UG8, AD8 and MW) (termed "triple mix") Dairy cows (one pregnant and one non-pregnant). All four cows received at least 3 vaccinations, with the last vaccination given 4 weeks before farrowing. All four cows seroconverted within 9 weeks. The reciprocal endpoint serum IgG titer for pregnant dairy cows was up to 1×10 as determined by a newly established anti-bovine IgG H...

Embodiment 3

[0199] Example 3: Polyclonal neutralizing antibodies against HIV-1 Env from bovine colostrum

[0200] Twelve BSE-free pregnant dairy cows housed on an authorized isolation farm in Victoria were vaccinated with 100 μg of an equimolar mixture of four HIV-1 Env gp140 oligomers:

[0201] 1) SC35 B clade pre-seroconversion strain Env gp140, which adopts an open structure and mainly exhibits important neutralizing epitopes;

[0202] 2) ADA primary R5 tropism B clade Env gp140;

[0203] 3) 966 A / E clade Env gp140; and

[0204] 4) MW C clade Env gp140.

[0205] These Envs were formulated with an adjuvant (Montanide) and administered by a registered veterinarian twice before conception and at least twice at 3-week intervals during the second trimester.

[0206] Env-specific IgG levels in routine blood samples taken during the vaccination and pregnancy were monitored using the Env ELISA test and Western blot, and vaccination was continued until high titers of IgG were detected. The ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides methods and compositions useful in the field of medicine, and particularly in the treatment of viral infections. More particularly, the invention relates to the use of methods and compositions for the inhibition of human immunodeficiency virus (HIV) transmission.

Description

technical field [0001] The present invention provides methods and compositions useful in the field of medicine, and in particular methods and compositions useful in the treatment of viral infections. More specifically, the present invention relates to methods and compositions for inhibiting the spread of human immunodeficiency virus (HIV). Background technique [0002] The retrovirus named Human Immunodeficiency Virus (HIV) is the causative agent of a complex disease that includes progressive destruction of the immune system (Acquired Immunodeficiency Syndrome; AIDS) and degeneration of the central and peripheral nervous systems. Since its emergence as a public health threat in the early 1980's, efforts to control or eliminate the disease have largely focused on options for the treatment of the disease once an individual has become infected. [0003] Condom use provides a considerable degree of protection against the transmission of HIV infection during sexual activity. Ho...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/42A61P31/18
CPCC07K16/04C07K16/1045C07K2317/76C07K2317/12C07K2317/33A61P31/18A61P43/00
Inventor G.T.罗林D.F.J.普塞尔R.J.森特M.克拉姆斯基R.M.罗宾斯-布朗G.里奇蒂
Owner REEF PHARMA PTY LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com